Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Yu

Orthopaedic Surgery Huntsville, AL Medical Doctor

NPI 1518345362 CMS profile 4220523

4715 Whitesburg Dr Se, Huntsville, AL 35802

Open in the dashboard

General payments

$1,237

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Yu of Huntsville, AL is reported in the CMS Open Payments database as having received $1,237 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $352 4
2024 General $306 2
2023 General $15 1
2022 General $201 3
2021 General $193 4
2020 General $85 2
2019 General $86 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Yu
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jonathan Yu were reported at $352. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jonathan Yu Orthopaedic Surgery median Middle half National median
2019 $86 $644 $140–$2,844 $163
2020 $85 $312 $75–$1,860 $114
2021 $193 $520 $117–$2,495 $132
2022 $201 $598 $128–$2,731 $149
2023 $15 $461 $128–$2,264 $160
2024 $306 $497 $134–$2,475 $164
2025 $352 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $409 5 payments
  2. Stryker Corporation $176 1 payment
  3. DePuy Synthes Sales Inc. $157 3 payments
  4. Prime Surgical, LLC $156 1 payment
  5. Medical Device Business Services, Inc. $110 1 payment
  6. ExsoMed Corporation $70 1 payment
  7. OMNIlife science, Inc $58 1 payment
  8. AxoGen $41 1 payment
  9. Bioventus LLC $32 2 payments
  10. Medtronic USA, Inc. $16 1 payment
  11. Other $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,237 18 payments
Products named General payments · program years 2019–2025
  1. EVOS Trauma Plates, Screws, and Nails $257 2 payments
  2. TRIGEN INTERTAN $225 2 payments
  3. PANGEA $176 1 payment
  4. VARIAX $176 1 payment
  5. TFN-Advance $121 1 payment
  6. EVOS Trauma Plates, Screws, and Nails $50 1 payment
  7. Avance Nerve Graft $41 1 payment
  8. VA-LCP $36 2 payments
  9. REGENETEN Shoulder $27 1 payment
  10. Fast-Fix 360 $27 1 payment
  11. Other $196 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

506

Median for Orthopedic Surgery: 203

Drug cost

$2,158

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 72 $743
Ibuprofen Generic 118 $333
Oxycodone Hcl Generic 114 $314
Gabapentin Generic 98 $270
Methylprednisolone Generic 26 $247
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $108
Tramadol Hcl Generic 30 $83
Cephalexin Generic 13 $61

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 132 billing codes

Paid by Medicare

$181,363

Of which drugs: $1,519

Medicare patients

432

Average age 75

Services billed

2,790

260 women, 172 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Ischemic heart disease 29%
Diabetes 28%
Depression 27%
Chronic kidney disease 26%
Atrial fibrillation 22%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 128 276 $1,455

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record